US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith
  
Number step 1, 2, 3 graphical representation of the process
The AAM CEO suggested the FDA take a more step-wise approach to its new ANDA pilot. (Shutterstock)

More from Regulation

More from Policy & Regulation